Phibro Animal Health Q1 FY27 Adjusted Net Income Rises 9% to $32.4 Million

• Phibro Animal Health’s first-quarter FY27 adjusted diluted EPS rose 8% year over year to $0.79.
• Net sales climbed 6% to $386.8 million, with Mineral Nutrition benefiting from higher demand and average selling prices.
• Guidance assumes no additional virginiamycin sales in Brazil for the fiscal year; regulatory approval would represent potential upside.
• FY27 guidance remained unchanged, including adjusted EBITDA of $258 million–$268 million and adjusted diluted EPS of $3.41–$3.59.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041622BIZWIRE_USPR_____20261102_BW016605) on November 04, 2026, and is solely responsible for the information contained therein.